Direct answer. Rheumatic heart disease, or RHD, is acquired heart-valve damage following rheumatic fever, an immune reaction after group A streptococcal infection. Preventing another episode of rheumatic fever and treating existing valve disease are related but different tasks. Confidence is high in this distinction and in the need for clinical follow-up. An antibiotic plan does not replace assessment of a narrowed or leaking valve. CDC rheumatic fever and investigation, August2025; WHO rheumatic heart disease fact sheet, January2025.
- RHD is acquired after rheumatic fever; it is not a congenital valve defect.
- Rheumatic fever can affect joints, skin, brain and heart, and has no single confirming test.
- Secondary antibiotic prevention addresses recurrent infection/fever risk; valve assessment addresses existing damage.
- An early screening finding and advanced symptomatic valve disease require different decisions.
- Pregnancy, worsening breathlessness, new rhythm symptoms and stroke signs need an appropriate clinical pathway.
Evidence summary
| Question | Source role | Conclusion and confidence |
|---|---|---|
| What causes the valve injury? | Public clinical education | An immune-mediated consequence of rheumatic fever after group A strep infection. |
| What does preventive antibiotic care target? | Attributed prevention guidance | Recurrent infection/fever risk; it is not a mechanical valve repair. |
| Can a symptom checklist diagnose RHD? | Diagnostic education | No. Valve imaging and clinical interpretation are needed. |
| Does the GOAL original supply a fully independent efficacy estimate? | Financially screened source role | No. Corporate-foundation backing means strict exclusion; methods and harms remain informative. |
Confidence is high in the condition distinctions and need for appropriate assessment. The treatment section attributes clinical guidance; it does not certify the funding of every underlying intervention trial. Independent comparative outcome certainty and a supplement replacement regimen were not established by this focused review. A public institution or independent review cannot make a sponsored original trial financially independent.
What it is
Rheumatic fever is an inflammatory illness that can follow a group A strep infection. It may involve the heart, joints, skin or brain. RHD refers to the resulting longer-term valve disease, rather than every fever, sore throat or painful joint. Rheumatic fever itself is an immune response and cannot be caught from another person, although the bacteria responsible for an active infection can spread. CDC rheumatic fever and investigation, August2025.
The diagnosis should name the affected valves and their actual findings. Acquired rheumatic disease differs from a valve that developed abnormally before birth, degenerative valve disease and infection of a valve. Several causes can produce similar symptoms, so the word rheumatic should have a clinical basis rather than follow automatically from an abnormal scan. NHLBI valve disease causes, March2022.
How it works
The valve leaflets normally open to allow forward flow and close to limit backward flow. A narrowed opening is stenosis; failure to close effectively produces regurgitation. These findings can coexist, and different valves can have different problems. A report describing a leak therefore does not establish either the cause or the importance of that leak. NHLBI valve anatomy and types, March2022.
Repeated inflammatory injury can add to existing valve damage. That is why a prevention plan may continue long after the initial illness has settled. Relief of painful joints or disappearance of fever does not establish that every heart finding has resolved. Conversely, the existence of a mild valve finding does not mean someone inevitably needs an immediate operation. NHS rheumatic fever, January2025; NHLBI valve care background, March2022.
The work imposed on the heart depends on which valve is involved, the degree of obstruction or leakage and the heart’s response. Breathlessness, fatigue, swelling and palpitations can occur, but also have other causes. Imaging and clinical assessment connect symptoms with valve function and help avoid treating an assumed cause. NHLBI valve disease symptoms, March2022.
The evidence-based treatments
There are separate clinical goals: treat a current group A strep infection, manage an episode of rheumatic fever, prevent recurrences and address established valve disease or complications. The CDC describes antimicrobial treatment and medicines for inflammatory symptoms in acute rheumatic fever. This is attributed clinical guidance; the guide supplies no antibiotic choice, injection schedule or anti-inflammatory regimen for self-treatment. CDC rheumatic fever and investigation, August2025.
The NHS describes preventive antibiotic treatment over a prolonged period after rheumatic fever. The responsible clinician should explain why prevention is recommended, its planned duration and how allergies or difficulty obtaining treatment will be handled. Do not stop because symptoms have disappeared or copy a schedule from someone with a different history. NHS rheumatic fever, January2025.
Valve care can involve observation, medicines for an established complication, and selected valve repair or replacement. The general NHLBI source describes these categories, but does not settle which approach suits an individual rheumatic valve. Ask whether the present goal is controlling congestion or rhythm, preventing a clot, relieving obstruction or correcting leakage. NHLBI valve care background, March2022.
The original GOAL trial studied young Ugandan participants with latent disease, comparing preventive penicillin with no prophylaxis and using blinded echo adjudication. Its report also documents treatment-related anaphylaxis and nerve injury. Philips Foundation appears among its backers, with an actual Royal Philips financial chain. It is methods/safety context here; its reported benefit is not used to certify an independently funded treatment verdict or an adult structural-valve outcome. GOAL original2022 penicillin trial, unchanged PASCAR mirror; Philips Foundation original2024 operational and financial policy.
For selected rheumatic mitral stenosis, specialist options include percutaneous mitral commissurotomy, a balloon procedure that separates fused commissures, or surgery. The actual2025 ESC/EACTS section10.2 bases selection on symptoms, valve/subvalvular anatomy and other findings. A coexisting leak, a clot or other valve disease can change suitability. This is attributed C-provisional guidance, not a promise of benefit or a universal catheter alternative. Original 2025 ESC/EACTS valve guideline, society-hosted OUP PDF.
Supplement and lifestyle evidence
No supplement is established by this review as a replacement for indicated antibiotic prevention, an acute rheumatic-fever assessment or treatment of important valve disease. An immune-support claim does not establish prevention of recurrent rheumatic fever. A laboratory anti-inflammatory effect also cannot show that a narrowed valve has become functionally adequate.
Ask the clinician about appropriate physical activity rather than using breathlessness as an instruction to push through or abandon movement entirely. Nutrition, smoking cessation and other ordinary cardiovascular care support general health, but their goals should be separated from correction of valve anatomy. The valve-treatment source recommends matching activity to clinical status. NHLBI valve care background, March2022.
What works and what does not
Organize the clinical record around the specific problem: prior rheumatic-fever history, valve findings, symptoms, preventive treatment and any previous procedure. A clear distinction between these items helps a new clinician understand why an antibiotic is being used even when a heart medicine has a different purpose. This is a consultation aid, not a diagnostic scoring system.
Access is part of prevention. WHO describes crowding, poor housing and barriers to prompt care as important contexts. A missed clinic visit may reflect transport, work, cost, pain or medicine supply rather than lack of concern. Tell the service about the practical obstacle so an achievable plan can be discussed. This does not justify delaying urgent symptoms while a routine access problem is being solved. WHO rheumatic heart disease fact sheet, January2025.
Risks and side effects
Seek emergency help for severe chest discomfort, serious difficulty breathing, collapse or sudden neurological symptoms such as facial weakness, arm weakness or speech difficulty. An established RHD label does not identify the cause of a new emergency or make it safe to wait for the usual clinic. NHLBI stroke and TIA emergency symptoms, May2023; NHLBI valve disease symptoms, March2022.
New or worsening symptoms warrant review even when a previous echo was reassuring. Following rheumatic fever, recurrent fever, painful swollen joints or involuntary movements should also be assessed rather than assumed to be ordinary recovery. A symptom record can describe timing and change; it cannot identify the valve grade or rule out a new episode. NHS rheumatic fever, January2025.
Procedures and medicines have different harms. General valve education describes bleeding, clotting, stroke, kidney injury and recurrent structural problems among potential procedural risks. These are categories for informed discussion, not a personal risk estimate. Ask which risks apply to the proposed intervention and current circumstances. NHLBI valve care background, March2022.
Important interactions
Preventive antibiotics, medicines for congestion or rhythm and anticoagulants can coexist for distinct reasons. Bring one complete list to the clinician or pharmacist, including non-prescription painkillers and supplements. The fact that a product is sold without a prescription does not establish that it is appropriate alongside a prescribed anticoagulant or in impaired kidney function.
Anticoagulation is not automatically indicated for everyone with RHD. A rhythm finding, a particular replacement valve or another clot-risk indication changes the decision. Confirm the established indication and monitoring rather than interpreting “valve disease” as a universal blood-thinner instruction. A mechanical-valve medicine plan also differs from the antibiotic plan used to prevent recurrent rheumatic fever. NHLBI valve care background, March2022.
The anticoagulant class also matters. The2025 professional guidance distinguishes significant rheumatic mitral stenosis with atrial fibrillation and mechanical-valve care from situations where a direct oral anticoagulant may be suitable. Confirm the actual valve and rhythm indication with the prescriber; do not replace a vitamin K antagonist with a newer agent or change its monitoring from a general internet comparison. Original 2025 ESC/EACTS valve guideline, society-hosted OUP PDF.
Who needs assessment
A previous episode of rheumatic fever, a new murmur, unexplained persistent symptoms or a clinician-detected valve finding merits an appropriate assessment. CDC explains that rheumatic fever has no single diagnostic test: history, examination, evidence of recent infection, ECG and echo have complementary roles. A positive throat test alone does not diagnose heart damage. CDC rheumatic fever and investigation, August2025.
Echo assesses the valves and heart response; Doppler helps characterize blood flow. An ECG addresses electrical activity rather than displaying the same structural information. Ask the clinician to explain what each result establishes, what remains uncertain and whether a later comparison is needed. A murmur heard with a stethoscope is a finding, not a full severity measurement. NHLBI valve disease diagnosis, March2022.
Pregnancy planning requires valve and medicine review. Pregnancy can change circulatory workload, and important stenosis, heart dysfunction or a replacement-valve anticoagulant plan may create specific risks. Arrange specialist assessment before pregnancy where possible; if already pregnant, tell the team promptly. This review provides no individual pregnancy-risk category or instruction to change anticoagulation. NHLBI valve disease and pregnancy, March2022.
Clinician-led use and follow-up
Ask for a written plan identifying the prevention indication, responsibility for prescriptions, how missed treatment is handled and when reassessment is due. Keep allergy details and prior reactions specific: name the product and describe what happened. Do not intentionally re-expose yourself to test whether an allergy was real.
Follow-up should distinguish infection-prevention review from valve surveillance and review of a complication. After a valve procedure, confirm the new valve description, medicine indications and responsible follow-up service. A technically successful intervention does not make every future infection, rhythm or clot question disappear. NHLBI valve care background, March2022.
No dose, injection interval, duration cutoff or home diagnostic threshold is supplied here. Local guidance, age, exposure risk, disease history, allergy, pregnancy and current clinical status can change a plan. Ask what finding would lead the treating service to alter its recommendation and how uncertainty will be revisited.
Animal and in-vitro evidence
Cell and animal experiments on vessel function or cardiac stress can suggest mechanisms. They do not establish safe human dosing, symptom improvement or fewer serious events. A laboratory preparation and a retail product may differ in composition, absorption and exposure. No animal or in-vitro result contributes to the independent clinical verdict in this guide.
Funding and source roles
Who paid for the evidence?
Follow named sources to the funding and relationships disclosed in this article. Numbered article disclosures preserve notes where a source is not identified. A public or university name alone does not establish independence.
View 31 more funding disclosures
This graphic reorganizes the article's disclosures; it is not a new financial audit or independence classification. Highlighted notes show different funding relationships where available. Review funding is separate from underlying trial funding. Disclosure is not proof of falsehood, and no declared conflict is not proof of complete independence.
RHD has no corporate owner. Antibiotic suppliers, valve/device manufacturers, imaging providers and procedural services have distinct interests. WHO development funding is explicitly disclosed, while the major trial’s corporate-foundation backing is independently traced and excluded from the efficacy verdict. Full trial-author and remaining backer chains are unresolved.
The condition has no corporate owner. Medicines, diagnostics, devices, procedures and marketed supplements create different revenue incentives. This describes financial interests rather than misconduct. Funding tier evaluates proximity to the subject; A–D credibility assesses transparency, accuracy incentives and remaining uncertainty. An unresolved link stays unresolved, and a provisional public-information label does not clear the trials behind it.
| Source | Funding / backers | Country / jurisdiction | Independence | Credibility / incentives / gaps |
|---|---|---|---|---|
| WHO rheumatic heart disease fact sheet, January2025 | WHO institution: assessed member-state dues and voluntary contributions from states, intergovernmental bodies, foundations and private-sector/other donors; actual financing routes. Earmarking and full institutional donor chain unresolved; no donor is assigned to this page without evidence. | Switzerland; WHO headquarters Geneva; intergovernmental global-health body. Guideline contributors work in multiple countries; NLM US hosts an unchanged WHO original, not its producer. | Tier 1 intergovernmental public education provisional; exact page budget and author/trial finances unresolved. | B provisional. Public-health mandate and explicit dates favour accurate education; policy priorities, simplification and incomplete page/underlying-study tracing remain. Role: January2025 condition definition and social/pregnancy context. |
| WHO2024 rheumatic fever/RHD guideline original scope | WHO institution: assessed member-state dues and voluntary contributions from states, intergovernmental bodies, foundations and private-sector/other donors; actual financing routes. Earmarking and full institutional donor chain unresolved; no donor is assigned to this page without evidence. Actual2024 acknowledgements say WHO MCA and NCD departments funded guideline development without external funders. Contributor annex records Beaton and Mocumbi involvement in included studies, judged nonsignificant by WHO. This is intellectual involvement, not proof of an undisclosed financial tie; it does not clear underlying trial finance. | Switzerland; WHO headquarters Geneva; intergovernmental global-health body. Guideline contributors work in multiple countries; NLM US hosts an unchanged WHO original, not its producer. | Tier 2 intergovernmental guideline development, provisional; independent original-trial efficacy not cleared. | B provisional for the actual scope and disclosed development chain. Guideline scope, acknowledgements and contributor annex read; full recommendation chapter/PDF access failed. No complete guideline review or independent clearance of its original trials is claimed. Study-author involvement can create intellectual allegiance. Role: Actual2024 guideline scope only; full recommendation chapter not read. |
| WHO2024 original guideline acknowledgements and funding | WHO institution: assessed member-state dues and voluntary contributions from states, intergovernmental bodies, foundations and private-sector/other donors; actual financing routes. Earmarking and full institutional donor chain unresolved; no donor is assigned to this page without evidence. Actual2024 acknowledgements say WHO MCA and NCD departments funded guideline development without external funders. Contributor annex records Beaton and Mocumbi involvement in included studies, judged nonsignificant by WHO. This is intellectual involvement, not proof of an undisclosed financial tie; it does not clear underlying trial finance. | Switzerland; WHO headquarters Geneva; intergovernmental global-health body. Guideline contributors work in multiple countries; NLM US hosts an unchanged WHO original, not its producer. | Tier 3 institutional financial, declaration or contact self-disclosure. | B provisional for reported financing, declarations and location. Explicit development funding and published contributors enable checking; donor allocations, completeness and original-trial chains remain unresolved. Financial provenance only. |
| WHO2024 original contributor declarations | WHO institution: assessed member-state dues and voluntary contributions from states, intergovernmental bodies, foundations and private-sector/other donors; actual financing routes. Earmarking and full institutional donor chain unresolved; no donor is assigned to this page without evidence. Actual2024 acknowledgements say WHO MCA and NCD departments funded guideline development without external funders. Contributor annex records Beaton and Mocumbi involvement in included studies, judged nonsignificant by WHO. This is intellectual involvement, not proof of an undisclosed financial tie; it does not clear underlying trial finance. | Switzerland; WHO headquarters Geneva; intergovernmental global-health body. Guideline contributors work in multiple countries; NLM US hosts an unchanged WHO original, not its producer. | Tier 3 institutional financial, declaration or contact self-disclosure. | B provisional for reported financing, declarations and location. Explicit development funding and published contributors enable checking; donor allocations, completeness and original-trial chains remain unresolved. Financial provenance only. |
| WHO assessed and voluntary funding routes | WHO institution: assessed member-state dues and voluntary contributions from states, intergovernmental bodies, foundations and private-sector/other donors; actual financing routes. Earmarking and full institutional donor chain unresolved; no donor is assigned to this page without evidence. | Switzerland; WHO headquarters Geneva; intergovernmental global-health body. Guideline contributors work in multiple countries; NLM US hosts an unchanged WHO original, not its producer. | Tier 3 institutional financial, declaration or contact self-disclosure. | B provisional for reported financing, declarations and location. Explicit development funding and published contributors enable checking; donor allocations, completeness and original-trial chains remain unresolved. Financial provenance only. |
| WHO actual Geneva headquarters contact | WHO institution: assessed member-state dues and voluntary contributions from states, intergovernmental bodies, foundations and private-sector/other donors; actual financing routes. Earmarking and full institutional donor chain unresolved; no donor is assigned to this page without evidence. | Switzerland; WHO headquarters Geneva; intergovernmental global-health body. Guideline contributors work in multiple countries; NLM US hosts an unchanged WHO original, not its producer. | Tier 3 institutional financial, declaration or contact self-disclosure. | B provisional for reported financing, declarations and location. Explicit development funding and published contributors enable checking; donor allocations, completeness and original-trial chains remain unresolved. Financial provenance only. |
| NHS rheumatic fever, January2025 | DHSC funds the national NHS website; its policy states no advertising or corporate sponsorship. Named authors, page-level budget and full underlying trial conflicts unresolved. | United Kingdom; England national public-information service. Other jurisdictions have different services. | Tier 1 public education provisional; not a clearance of original studies. | B provisional. Public-service remit and editorial checks support accuracy; simplification, service priorities and incomplete trial-finance tracing limit inference. Role: January2025 acute illness, recurrence and follow-up context. |
| CDC rheumatic fever and investigation, August2025 | CDC/HHS federal budget authority and public transfers in FY2026 operating plan. Separate gift authority permits donations, bequests, in-kind support and CDC Foundation transfers with conflict review. These permitted routes do not prove a private gift financed this page. Named donors, page allocation and author/original-study finances unresolved. | United States; CDC Atlanta, Georgia, federal public-health jurisdiction. Archived surveillance handbook has international partner links; complete partner and backer financial chains not cleared. | Tier 1 public education provisional; gift, donor and full page-specific chain unresolved. | B provisional. Public accountability and explicit source/review dates aid checking; policy priorities, simplification and untraced underlying studies limit independent inference. Role: August2025 immune mechanism, testing and prevention context. |
| NHLBI valve disease causes, March2022 | US federal appropriations; separate Gift Fund accepts donations and bequests, including support for public health information. Budget route; Gift authority. Actual donors, page allocation and underlying trial finances unresolved. | United States; NIH/NHLBI, Bethesda, Maryland; federal jurisdiction. | Tier 1 public education provisionally; donation route and page-specific chain unresolved. | B provisional. Public accountability and educational review favour accuracy; institutional priorities, simplification, dated wording and untraced trial ties remain. Role: Acquired versus congenital valve background. |
| NHLBI valve anatomy and types, March2022 | US federal appropriations; separate Gift Fund accepts donations and bequests, including support for public health information. Budget route; Gift authority. Actual donors, page allocation and underlying trial finances unresolved. | United States; NIH/NHLBI, Bethesda, Maryland; federal jurisdiction. | Tier 1 public education provisionally; donation route and page-specific chain unresolved. | B provisional. Public accountability and educational review favour accuracy; institutional priorities, simplification, dated wording and untraced trial ties remain. Role: Valve obstruction/leakage anatomical background. |
| NHLBI valve disease symptoms, March2022 | US federal appropriations; separate Gift Fund accepts donations and bequests, including support for public health information. Budget route; Gift authority. Actual donors, page allocation and underlying trial finances unresolved. | United States; NIH/NHLBI, Bethesda, Maryland; federal jurisdiction. | Tier 1 public education provisionally; donation route and page-specific chain unresolved. | B provisional. Public accountability and educational review favour accuracy; institutional priorities, simplification, dated wording and untraced trial ties remain. Role: Symptoms cannot identify cause or severity alone. |
| NHLBI valve disease diagnosis, March2022 | US federal appropriations; separate Gift Fund accepts donations and bequests, including support for public health information. Budget route; Gift authority. Actual donors, page allocation and underlying trial finances unresolved. | United States; NIH/NHLBI, Bethesda, Maryland; federal jurisdiction. | Tier 1 public education provisionally; donation route and page-specific chain unresolved. | B provisional. Public accountability and educational review favour accuracy; institutional priorities, simplification, dated wording and untraced trial ties remain. Role: Echo, Doppler and electrical investigation roles. |
| NHLBI valve care background, March2022 | US federal appropriations; separate Gift Fund accepts donations and bequests, including support for public health information. Budget route; Gift authority. Actual donors, page allocation and underlying trial finances unresolved. | United States; NIH/NHLBI, Bethesda, Maryland; federal jurisdiction. | Tier 1 public education provisionally; donation route and page-specific chain unresolved. | B provisional. Public accountability and educational review favour accuracy; institutional priorities, simplification, dated wording and untraced trial ties remain. Role: General structural and complication-care context, not RHD procedure comparisons. |
| Original 2025 ESC/EACTS valve guideline, society-hosted OUP PDF | The original guideline states document development was financed entirely by ESC and EACTS without healthcare-industry involvement. ESC institutional revenues nevertheless include life-science and medtech partnerships; EACTS discloses industry/charity grants and an Edwards Lifesciences Foundation partnership. That separate route does not prove Edwards funded this guideline. The official 2025 author declaration report returned 403 and was not read. Article allocation, individual author independence and original device/drug trial chains remain unresolved. | France: ESC, Sophia Antipolis. United Kingdom: EACTS, Windsor, registered England and Wales; OUP publisher UK. International writing panel. The unchanged original EJCTS PDF mirror is hosted by MATCVS, Malaysia; it does not change the document author or funding origin. Edwards corporate headquarters Irvine, California, US; specific supplied-device manufacturing origin unresolved. | Tier 2 documented society industry routes, with unresolved author chain; independent efficacy excluded. | C provisional. Original 109-page guideline and August 2026 correction checked. Detailed methodology, specialist review and explicit evidence grades aid attributed clinical use; society commercial routes, inaccessible author declarations and uncleared original-trial finances prevent a clean independent outcome verdict. Role: Actual rheumatic mitral-stenosis section10.2 and procedural/antithrombotic context, C-provisional. |
| Official August6,2026 correction to2025 valve guideline | The original guideline states document development was financed entirely by ESC and EACTS without healthcare-industry involvement. ESC institutional revenues nevertheless include life-science and medtech partnerships; EACTS discloses industry/charity grants and an Edwards Lifesciences Foundation partnership. That separate route does not prove Edwards funded this guideline. The official 2025 author declaration report returned 403 and was not read. Article allocation, individual author independence and original device/drug trial chains remain unresolved. | France: ESC, Sophia Antipolis. United Kingdom: EACTS, Windsor, registered England and Wales; OUP publisher UK. International writing panel. The unchanged original EJCTS PDF mirror is hosted by MATCVS, Malaysia; it does not change the document author or funding origin. Edwards corporate headquarters Irvine, California, US; specific supplied-device manufacturing origin unresolved. | Tier 2 documented society industry routes, with unresolved author chain; independent efficacy excluded. | C provisional. Original 109-page guideline and August 2026 correction checked. Detailed methodology, specialist review and explicit evidence grades aid attributed clinical use; society commercial routes, inaccessible author declarations and uncleared original-trial finances prevent a clean independent outcome verdict. Role: Actual August2026 correction; original guideline NYHA transcription corrected. |
| NHLBI valve disease and pregnancy, March2022 | US federal appropriations; separate Gift Fund accepts donations and bequests, including support for public health information. Budget route; Gift authority. Actual donors, page allocation and underlying trial finances unresolved. | United States; NIH/NHLBI, Bethesda, Maryland; federal jurisdiction. | Tier 1 public education provisionally; donation route and page-specific chain unresolved. | B provisional. Public accountability and educational review favour accuracy; institutional priorities, simplification, dated wording and untraced trial ties remain. Role: Pregnancy needs valve/medicine review. |
| NHLBI stroke and TIA emergency symptoms, May2023 | US federal appropriations; separate Gift Fund accepts donations and bequests, including support for public health information. Budget route; Gift authority. Actual donors, page allocation and underlying trial finances unresolved. | United States; NIH/NHLBI, Bethesda, Maryland; federal jurisdiction. | Tier 1 public education provisionally; donation route and page-specific chain unresolved. | B provisional. Public accountability and educational review favour accuracy; institutional priorities, simplification, dated wording and untraced trial ties remain. Role: Emergency neurological symptom education. |
| GOAL original2022 penicillin trial, unchanged PASCAR mirror | Original p239 names Thrasher Research Fund, Gift of Life International, Children’s National Hospital Foundation (Zachary Blumenfeld Fund and Race for Every Child/Team Jocelyn), Elias–Ginsburg Family, Wiley Rein, Philips Foundation, AT&T Foundation, Heart Healers International, Karp Family Foundation, Huron Philanthropies and Cincinnati Children’s Hospital Heart Institute Research Core. Philips Foundation policy confirms manufacturer Royal Philips cash/in-kind backing. Exact trial contribution type/amount, penicillin supplier finance, other backer financial chains and complete author forms unresolved. | Trial Gulu, Uganda; coordinating corresponding author Cincinnati, US; international institutions. Royal Philips-linked Foundation Amsterdam, Netherlands. Full legal/HQ chains of remaining named backers unresolved. | Tier 4 manufacturer-linked funding through Philips Foundation; strict independent efficacy exclusion. | D for financial independence. Randomization and blinded echo adjudication support methods checking, separately from sponsorship. Open treatment, selected young latent-disease cohort, post-randomization reclassification and incomplete financial chains limit generalization. Methods/safety context only; no manufacturer-funded effect estimate supplies the independent verdict. |
| Philips Foundation original2024 operational and financial policy | Actual2024 policy identifies Royal Philips as founder and cash/in-kind contributor, including staff, premises and services; co-investors/other donors also possible. Separate not-for-profit legal form does not remove corporate proximity. Trial-specific contribution unresolved. | Amsterdam, Netherlands; Stichting Philips Foundation and wholly owned Impact Investments BV; exact product manufacture not traced. | Tier 4 direct corporate-linked foundation financial self-disclosure. | D for independence; B provisional for explicit corporate relationship/location provenance. Self-report and brand/impact incentives remain; no efficacy use. |
| Thrasher Research Fund original award and co-funding policy | Actual award policy describes external peer review, committee decisions and permitted co-funding from other sources. Current complete assets, originating wealth/ownership and donor chain were not retrieved; no clean independent grant certification is inferred. | US research-fund programme; complete current legal headquarters and donor jurisdictions unresolved in this focused audit. | Tier 3 funder programme and policy self-disclosure; complete backer chain unresolved. | B provisional for stated award process, not financial independence or efficacy. Research-impact promotion and incomplete donor tracing remain. Financial provenance only. |
| NHLBI valve disease definitions, March2022 | US federal appropriations; separate Gift Fund accepts donations and bequests, including support for public health information. Budget route; Gift authority. Actual donors, page allocation and underlying trial finances unresolved. | United States; NIH/NHLBI, Bethesda, Maryland; federal jurisdiction. | Tier 1 public education provisionally; donation route and page-specific chain unresolved. | B provisional. Public accountability and educational review favour accuracy; institutional priorities, simplification, dated wording and untraced trial ties remain. Role: Additional original linked in condition-specific education or follow-up. |
| NHLBI budget | US federal appropriations; separate Gift Fund accepts donations and bequests, including support for public health information. Budget route; Gift authority. Actual donors, page allocation and underlying trial finances unresolved. | United States; NIH/NHLBI, Bethesda, Maryland; federal jurisdiction. | Tier 3 institutional financial self-disclosure. | B provisional. Direct public financial policy, with legal accountability; actual gift donors and allocations not audited. Financial provenance only. |
| NHLBI Gift Fund | US federal appropriations; separate Gift Fund accepts donations and bequests, including support for public health information. Budget route; Gift authority. Actual donors, page allocation and underlying trial finances unresolved. | United States; NIH/NHLBI, Bethesda, Maryland; federal jurisdiction. | Tier 3 institutional financial self-disclosure. | B provisional. Direct public financial policy, with legal accountability; actual gift donors and allocations not audited. Financial provenance only. |
| NHS national website funding policy | DHSC funds the national NHS website; its policy states no advertising or corporate sponsorship. Named authors, page-level budget and full underlying trial conflicts unresolved. | United Kingdom; England national public-information service. Other jurisdictions have different services. | Tier 3 editorial and financial self-disclosure. | B provisional. Explicit funding policy; actual individual declarations and implementation not audited. Financial provenance only. |
| ESC funding and revenue model | ESC directly reports life-science and medtech partnership income alongside memberships, congresses, publishing and education. Its July 2026 policy manages industry remuneration and other interests; reporting a policy is not proof that all bias is removed. | France; ESC European Heart House, Sophia Antipolis; multinational professional society. | Tier 3 institutional self-disclosure; financially interested in its own governance description. | B provisional for stated revenue routes; C where relied on to certify its own clinical independence. Financial transparency supports checking; actual amounts, implementation and document allocations not audited. Financial provenance only. |
| ESC conflict management policy | ESC directly reports life-science and medtech partnership income alongside memberships, congresses, publishing and education. Its July 2026 policy manages industry remuneration and other interests; reporting a policy is not proof that all bias is removed. | France; ESC European Heart House, Sophia Antipolis; multinational professional society. | Tier 3 institutional self-disclosure; financially interested in its own governance description. | B provisional for stated revenue routes; C where relied on to certify its own clinical independence. Financial transparency supports checking; actual amounts, implementation and document allocations not audited. Financial provenance only. |
| EACTS current industry/charity grant and Edwards Foundation relationship | EACTS explicitly offers industry/charity-sponsored outreach grants and names Edwards Lifesciences Foundation for Every Heartbeat Matters; a separate industry-sponsorship contact is provided. Edwards confirms funding, product donations and matching-gift routes. EACTS annual revenue amounts, complete donor list, guideline allocation and individual author finances were not fully traced. This is a documented institutional relationship, not evidence that Edwards directly financed the valve guideline. | United Kingdom; EACTS House, Windsor, registered company and charity in England and Wales. Edwards corporate headquarters Irvine, California, United States; global manufacturing locations differ from grant or guideline jurisdiction. | Tier 3 institutional financial self-disclosure; society has a stake in its own governance description. | B provisional for documented relationships and registered contact; C if used to certify clinical independence. Direct named support improves transparency; amounts, contract terms, full donor and page/author chains remain unresolved. Financial provenance only. |
| EACTS industry sponsorship route | EACTS explicitly offers industry/charity-sponsored outreach grants and names Edwards Lifesciences Foundation for Every Heartbeat Matters; a separate industry-sponsorship contact is provided. Edwards confirms funding, product donations and matching-gift routes. EACTS annual revenue amounts, complete donor list, guideline allocation and individual author finances were not fully traced. This is a documented institutional relationship, not evidence that Edwards directly financed the valve guideline. | United Kingdom; EACTS House, Windsor, registered company and charity in England and Wales. Edwards corporate headquarters Irvine, California, United States; global manufacturing locations differ from grant or guideline jurisdiction. | Tier 3 institutional financial self-disclosure; society has a stake in its own governance description. | B provisional for documented relationships and registered contact; C if used to certify clinical independence. Direct named support improves transparency; amounts, contract terms, full donor and page/author chains remain unresolved. Financial provenance only. |
| EACTS registered jurisdiction and Windsor contact | EACTS explicitly offers industry/charity-sponsored outreach grants and names Edwards Lifesciences Foundation for Every Heartbeat Matters; a separate industry-sponsorship contact is provided. Edwards confirms funding, product donations and matching-gift routes. EACTS annual revenue amounts, complete donor list, guideline allocation and individual author finances were not fully traced. This is a documented institutional relationship, not evidence that Edwards directly financed the valve guideline. | United Kingdom; EACTS House, Windsor, registered company and charity in England and Wales. Edwards corporate headquarters Irvine, California, United States; global manufacturing locations differ from grant or guideline jurisdiction. | Tier 3 institutional financial self-disclosure; society has a stake in its own governance description. | B provisional for documented relationships and registered contact; C if used to certify clinical independence. Direct named support improves transparency; amounts, contract terms, full donor and page/author chains remain unresolved. Financial provenance only. |
| Edwards corporate/foundation funding and technology-donation routes | Edwards Lifesciences corporate/foundation self-disclosure. It describes charitable funding, technology donations, employee matching and annual recipients. Corporate device sales and reputation create a direct interest; no corporate clinical outcome claim is used as independent evidence. Foundation-wide donors, grant contract terms and specific product provenance were not audited. | United States; Edwards Lifesciences corporate global headquarters Irvine, California. The opened location page names US manufacturing and says manufacturing is multinational; a headquarters is not the origin of every implant. | Tier 4 maker-associated corporate/foundation self-disclosure; clinical outcome claims excluded. | D for clinical promotion; provisional B only for explicit self-reported addresses and funding routes cross-checked with EACTS. Commercial and reputational incentives remain. Financial provenance only. |
| Edwards global headquarters and manufacturing-location disclosure | Edwards Lifesciences corporate/foundation self-disclosure. It describes charitable funding, technology donations, employee matching and annual recipients. Corporate device sales and reputation create a direct interest; no corporate clinical outcome claim is used as independent evidence. Foundation-wide donors, grant contract terms and specific product provenance were not audited. | United States; Edwards Lifesciences corporate global headquarters Irvine, California. The opened location page names US manufacturing and says manufacturing is multinational; a headquarters is not the origin of every implant. | Tier 4 maker-associated corporate/foundation self-disclosure; clinical outcome claims excluded. | D for clinical promotion; provisional B only for explicit self-reported addresses and funding routes cross-checked with EACTS. Commercial and reputational incentives remain. Financial provenance only. |
| CDC original FY2026 operating plan | CDC/HHS federal budget authority and public transfers in FY2026 operating plan. Separate gift authority permits donations, bequests, in-kind support and CDC Foundation transfers with conflict review. These permitted routes do not prove a private gift financed this page. Named donors, page allocation and author/original-study finances unresolved. | United States; CDC Atlanta, Georgia, federal public-health jurisdiction. Archived surveillance handbook has international partner links; complete partner and backer financial chains not cleared. | Tier 3 institutional finance, policy or contact self-disclosure. | B provisional for documented finance routes and location. Gift policy is dated2016 with2022 editorial review; actual donors, implementation, page allocations and individual independence not audited. Financial provenance only. |
| CDC dated2016 gift authority,2022 editorial review | CDC/HHS federal budget authority and public transfers in FY2026 operating plan. Separate gift authority permits donations, bequests, in-kind support and CDC Foundation transfers with conflict review. These permitted routes do not prove a private gift financed this page. Named donors, page allocation and author/original-study finances unresolved. | United States; CDC Atlanta, Georgia, federal public-health jurisdiction. Archived surveillance handbook has international partner links; complete partner and backer financial chains not cleared. | Tier 3 institutional finance, policy or contact self-disclosure. | B provisional for documented finance routes and location. Gift policy is dated2016 with2022 editorial review; actual donors, implementation, page allocations and individual independence not audited. Financial provenance only. |
| CDC actual Atlanta contact and public-site provenance | CDC/HHS federal budget authority and public transfers in FY2026 operating plan. Separate gift authority permits donations, bequests, in-kind support and CDC Foundation transfers with conflict review. These permitted routes do not prove a private gift financed this page. Named donors, page allocation and author/original-study finances unresolved. | United States; CDC Atlanta, Georgia, federal public-health jurisdiction. Archived surveillance handbook has international partner links; complete partner and backer financial chains not cleared. | Tier 3 institutional finance, policy or contact self-disclosure. | B provisional for documented finance routes and location. Gift policy is dated2016 with2022 editorial review; actual donors, implementation, page allocations and individual independence not audited. Financial provenance only. |
Frequently asked questions
Is RHD the same as rheumatic fever? No. Rheumatic fever is the inflammatory illness; RHD is the associated longer-term valve disease. NHS rheumatic fever, January2025.
Can RHD be present without current fever? Yes. An old inflammatory episode and present valve function are separate questions. A current absence of fever cannot clear a valve finding. NHLBI valve disease diagnosis, March2022.
Can an antibiotic repair a narrowed valve? Preventive antimicrobial care and structural valve treatment have different purposes. The assessment should explain both when they apply. NHLBI valve care background, March2022.
Does everyone need surgery or an anticoagulant? No universal plan follows from the name alone. Anatomy, severity, symptoms, rhythm and prior procedures determine the questions for the treating team. NHLBI valve care background, March2022.
Sources and funding notes
- WHO rheumatic heart disease fact sheet, January2025 — January2025 condition definition and social/pregnancy context.
- WHO2024 rheumatic fever/RHD guideline original scope — Actual2024 guideline scope only; full recommendation chapter not read.
- WHO2024 original guideline acknowledgements and funding — Actual original guideline-development funding, not trial clearance.
- WHO2024 original contributor declarations — Actual named contributor declarations and study-author involvement.
- WHO assessed and voluntary funding routes — Financial provenance only.
- WHO actual Geneva headquarters contact — Financial/location provenance only.
- NHS rheumatic fever, January2025 — January2025 acute illness, recurrence and follow-up context.
- CDC rheumatic fever and investigation, August2025 — August2025 immune mechanism, testing and prevention context.
- NHLBI valve disease causes, March2022 — Acquired versus congenital valve background.
- NHLBI valve anatomy and types, March2022 — Valve obstruction/leakage anatomical background.
- NHLBI valve disease symptoms, March2022 — Symptoms cannot identify cause or severity alone.
- NHLBI valve disease diagnosis, March2022 — Echo, Doppler and electrical investigation roles.
- NHLBI valve care background, March2022 — General structural and complication-care context, not RHD procedure comparisons.
- Original 2025 ESC/EACTS valve guideline, society-hosted OUP PDF — Actual rheumatic mitral-stenosis section10.2 and procedural/antithrombotic context, C-provisional.
- Official August6,2026 correction to2025 valve guideline — Actual August2026 correction; original guideline NYHA transcription corrected.
- NHLBI valve disease and pregnancy, March2022 — Pregnancy needs valve/medicine review.
- NHLBI stroke and TIA emergency symptoms, May2023 — Emergency neurological symptom education.
- GOAL original2022 penicillin trial, unchanged PASCAR mirror — Manufacturer-linked trial methods/safety only; independent outcome verdict excluded.
- Philips Foundation original2024 operational and financial policy — Actual manufacturer-linked financial chain.
- Thrasher Research Fund original award and co-funding policy — Actual grant/co-funding policy with unresolved complete donor chain.
- NHLBI valve disease definitions, March2022 — Additional original linked in condition-specific education or follow-up.
- NHLBI budget — Financial provenance only.
- NHLBI Gift Fund — Financial provenance only.
- NHS national website funding policy — Financial provenance only.
- ESC funding and revenue model — Financial provenance only.
- ESC conflict management policy — Financial provenance only.
- EACTS current industry/charity grant and Edwards Foundation relationship — Financial provenance only.
- EACTS industry sponsorship route — Financial provenance only.
- EACTS registered jurisdiction and Windsor contact — Financial provenance only.
- Edwards corporate/foundation funding and technology-donation routes — Financial provenance only.
- Edwards global headquarters and manufacturing-location disclosure — Financial provenance only.
- CDC original FY2026 operating plan — Financial provenance only.
- CDC dated2016 gift authority,2022 editorial review — Financial provenance only.
- CDC actual Atlanta contact and public-site provenance — Financial provenance only.
Original clinical pages and their relevant financial disclosures were opened. Actual WHO2024 scope, acknowledgements and contributor annex were read; full recommendations chapter and whole PDF access failed. Therefore no complete2024 guideline review is claimed. GOAL original11-page2022 paper read from unchanged PASCAR mirror including p239 finance; full separate author forms and complete other backer chains unresolved. Actual2024 Philips Foundation11-page policy confirms Royal Philips cash/in-kind support and Amsterdam location. Methods/harms context only, Tier4/D; original treatment effect excluded. The original 109-page 2025 ESC/EACTS valve guideline was read from MATCVS’s unchanged EJCTS/OUP PDF mirror, with its title, authors and DOI verified. The official August 6, 2026 correction was opened separately. The official author-declaration PDF returned 403 and was not read. Actual ESC, EACTS and Edwards financial-route disclosures were checked; separate institutional industry support does not establish direct industry financing of this document. Individual author and original-trial financial chains remain unresolved; clinical recommendations are C-provisional context. Clinical sources concentrate on US and English public education plus European professional guidance. This limits jurisdictional breadth: referral, implant availability and treatment systems vary, and no global access claim is inferred. Guidance, classification, emergency education and independent efficacy are distinct source roles. A full systematic review, complete society donor audit and author-by-author clearance of original treatment trials were not completed.
Last reviewed: October 4, 2026. Educational information, not a diagnosis or personal treatment plan. Use your local emergency service for an emergency.
Have a question — or want us to cover something?
Ask about anything on this page, or request the next deep dive: an ingredient, a supplement, or a health concern. We use published research, evidence syntheses, and regulatory guidance, with clear source links.
One daily research roundup
Get the topics, key findings and links from our new articles in one email. At most one digest a day, only when there is something new.